BRIGHT-4 Trial: Bivalirudin Strikes Back – Authors' Reply
Yi Li,Zhenyang Liang,Gregg W. Stone,Yaling Han
DOI: https://doi.org/10.1016/s0140-6736(23)00270-2
2023-01-01
Abstract:We thank Pierre-Guillaume Piriou and colleagues for their interest in our Article.1Li Y Liang Z Qin L et al.Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.Lancet. 2022; 400: 1847-1857Summary Full Text Full Text PDF PubMed Scopus (21) Google Scholar In the BRIGHT-4 trial, glycoprotein IIb/IIIa inhibition with tirofiban was used only for thrombotic complications during the percutaneous coronary intervention procedure. Use of these agents was not associated with an increased risk of major bleeding either with heparin or bivalirudin, as noted in the appendix of the Article (pp 15–16).1Li Y Liang Z Qin L et al.Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.Lancet. 2022; 400: 1847-1857Summary Full Text Full Text PDF PubMed Scopus (21) Google Scholar Although major bleeding was infrequent in both groups owing to the high rate of radial artery access, moderate bleeding occurred more frequently, and the incidence of severe bleeding could have been underestimated because the measurement of daily haemoglobin concentration was not required by the protocol. Moreover, although the rates of reported major bleeding were low, approximately 41% of the patients died after the occurrence of major bleeding within 30 days in both groups. In addition, nearly all the major bleeds that were prevented were non-access-site-related, the type that has been most strongly linked with subsequent mortality.2Verheugt FW Steinhubl SR Hamon M et al.Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.JACC Cardiovasc Interv. 2011; 4: 191-197Crossref PubMed Scopus (229) Google Scholar Approximately 50% of the reduction in stent thrombosis with bivalirudin occurred within 24 h and was probably related to the direct effects of the anticoagulants. Additionally, bivalirudin inhibits thrombin-induced platelet activation whereas heparin activates platelets. Greater platelet adhesion to the stent surface in patients treated with heparin within the first 24 h could explain the increased risk of stent thrombosis after this time when the antithrombotic effects of the anticoagulants are no longer present. A low stent area is associated with stent thrombosis, but there is no reason to think stent expansion should be different between groups in a randomised trial of two anticoagulants. Conversely, acute stent malapposition has never been related to stent thrombosis,3Mintz GS Ali Z Maehara A Use of intracoronary imaging to guide optimal percutaneous coronary intervention procedures and outcomes.Heart. 2021; 107: 755-764Crossref PubMed Scopus (9) Google Scholar which is a common misconception. Clopidogrel remains widely used in acute myocardial infarction in most countries, and as we noted in our Article1Li Y Liang Z Qin L et al.Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.Lancet. 2022; 400: 1847-1857Summary Full Text Full Text PDF PubMed Scopus (21) Google Scholar the relative treatment effects of bivalirudin compared with heparin were consistent in patients treated with ticagrelor and clopidogrel. As we also noted, we are not aware of genetic, social, or other differences between east Asian and other populations that should affect the relative outcomes of anticoagulant agents, and the BRIGHT-4 results were consistent with those from the European MATRIX trial.4Valgimigli M Frigoli E Leonardi S et al.Bivalirudin or unfractionated heparin in acute coronary syndromes.N Engl J Med. 2015; 373: 997-1009Crossref PubMed Scopus (314) Google Scholar However, we would recommend caution in interpreting the results from underpowered subgroups and have discussed in detail the specific interactions mentioned by Piriou and colleagues in our Article. Thus, although more data from under-represented cohorts would certainly be welcome, we believe the results from our trial are generalisable to most patients with ST-segment elevation myocardial infarctions. Given the substantially reduced cost of bivalirudin, the ease of use of the recommended regimen, and its predictability (obviating the need for frequent activating clotting time measures and dose adjustments), based on the results of BRIGHT-4 and previous trials, regular use of this agent rather than heparin in patients with ST-segment elevation myocardial infarctions having primary percutaneous coronary intervention offers the potential to prevent major bleeding and save tens of thousands of lives annually. GWS has received speaker honoraria from Abiomed, Infraredx, Medtronic, and Pulnovo; has served as a consultant to Abiomed, Ablative Solutions, Adona Medical, Amgen, Ancora, Apollo Therapeutics, Cardiomech, CorFlow, Elucid Bio, Gore, HeartFlow, Impulse Dynamics, Millennia Biopharma, Miracor, Neovasc, Occlutech, Robocath, TherOx, Valfix, and Vectorious; and has equity and options from Ancora, Applied Therapeutics, Aria, Biostar family of funds, Cagent, Cardiac Success, Orchestra Biomed, SpectraWave, Valfix, and Xenter. GWS's daughter is an employee at IQVIA. Institutional disclosure: GWS's employer, Mount Sinai Hospital, receives research support from Abbott, Abiomed, Biosense-Webster, Bioventrix, Cardiovascular Systems, Phillips, Pulnovo, Shockwave, Vascular Dynamics, and V-wave. All other authors declare no competing interests. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trialIn patients with STEMI undergoing primary PCI predominantly with radial artery access, anticoagulation with bivalirudin plus a post-PCI high-dose infusion for 2–4 h significantly reduced the 30-day composite rate of all-cause mortality or BARC types 3–5 major bleeding compared with heparin monotherapy. Full-Text PDF